 Chloride Channel Agonists
"Chloride Channel Agonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class of drugs that stimulate chloride ion influx through cell membrane channels.
| Descriptor ID |
D065101
|
| MeSH Number(s) |
D27.505.519.562.311
|
| Concept/Terms |
Chloride Channel Agonists- Chloride Channel Agonists
- Agonists, Chloride Channel
- Channel Agonists, Chloride
- Chloride Channel Activators
- Activators, Chloride Channel
- Channel Activators, Chloride
- Chloride Channel Stimulators
- Channel Stimulators, Chloride
- Stimulators, Chloride Channel
|
Below are MeSH descriptors whose meaning is more general than "Chloride Channel Agonists".
Below are MeSH descriptors whose meaning is more specific than "Chloride Channel Agonists".
This graph shows the total number of publications written about "Chloride Channel Agonists" by people in this website by year, and whether "Chloride Channel Agonists" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2007 | 0 | 1 | 1 | | 2012 | 0 | 1 | 1 | | 2015 | 0 | 2 | 2 | | 2016 | 1 | 1 | 2 | | 2017 | 1 | 2 | 3 | | 2018 | 3 | 2 | 5 | | 2019 | 4 | 3 | 7 | | 2020 | 5 | 0 | 5 | | 2021 | 7 | 3 | 10 | | 2022 | 0 | 3 | 3 | | 2023 | 0 | 7 | 7 | | 2024 | 1 | 5 | 6 | | 2025 | 1 | 2 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Chloride Channel Agonists" by people in Profiles.
-
Zemanick ET, Ramsey B, Sands D, McKone EF, Fajac I, Taylor-Cousar JL, Mall MA, Konstan MW, Nair N, Zhu J, Arteaga-Solis E, Van Goor F, McGarry L, Prieto-Centurion V, Sosnay PR, Bozic C, Waltz D, Mayer-Hamblett N. Sweat chloride reflects CFTR function and correlates with clinical outcomes following CFTR modulator treatment. J Cyst Fibros. 2025 Mar; 24(2):246-254.
-
Keating C, Yonker LM, Vermeulen F, Prais D, Linnemann RW, Trimble A, Kotsimbos T, Mermis J, Braun AT, O'Carroll M, Sutharsan S, Ramsey B, Mall MA, Taylor-Cousar JL, McKone EF, Tullis E, Floreth T, Michelson P, Sosnay PR, Nair N, Zahigian R, Martin H, Ahluwalia N, Lam A, Horsley A. Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials. Lancet Respir Med. 2025 Mar; 13(3):256-271.
-
Hoppe JE, Kasi AS, Pittman JE, Jensen R, Thia LP, Robinson P, Tirakitsoontorn P, Ramsey B, Mall MA, Taylor-Cousar JL, McKone EF, Tullis E, Salinas DB, Zhu J, Chen YC, Rodriguez-Romero V, Sosnay PR, Davies G. Vanzacaftor-tezacaftor-deutivacaftor for children aged 6-11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial. Lancet Respir Med. 2025 Mar; 13(3):244-255.
-
Metcalf A, Martiniano SL, Sagel SD, Zaretsky MV, Zemanick ET, Hoppe JE. Outcomes of prenatal use of elexacaftor/tezacaftor/ivacaftor in carrier mothers to treat meconium ileus in fetuses with cystic fibrosis. J Cyst Fibros. 2025 May; 24(3):466-468.
-
Jain R, Peng G, Lee M, Keller A, Cosmich S, Reddy S, West NE, Kazmerski TM, Goralski JL, Flume PA, Roe AH, Hadjiliadis D, Uluer A, Mody S, Ladores S, Taylor-Cousar JL. Impact of Cystic Fibrosis Transmembrane Conductance Regulator Modulators on Maternal Outcomes During and After Pregnancy. Chest. 2025 Feb; 167(2):348-361.
-
Costa E, Girotti S, Mathieu C, Castellani C, Ross JS, Taylor-Cousar JL, Leufkens HGM. Differential times of submission and approval of CFTR modulators for the treatment of Cystic Fibrosis in the United States and the European Union. J Cyst Fibros. 2025 Jan; 24(1):125-132.
-
Jia S, Wang Y, Ross MH, Zuckerman JB, Murray S, Han MK, Cahalan SE, Lenhan BE, Best RN, Taylor-Cousar JL, Simon RH, Fitzgerald LJ, Troost JP, Sood SL, Gifford AH. Association between CFTR modulators and changes in iron deficiency markers in cystic fibrosis. J Cyst Fibros. 2024 Sep; 23(5):878-884.
-
Duong JT, Pope CE, Hayden HS, Miller C, Salipante SJ, Rowe SM, Solomon GM, Nichols D, Hoffman LR, Narkewicz MR, Green N. Alterations in the fecal microbiota in patients with advanced cystic fibrosis liver disease after 6 months of elexacaftor/tezacaftor/ivacaftor. J Cyst Fibros. 2024 May; 23(3):490-498.
-
Zemanick ET, Emerman I, McCreary M, Mayer-Hamblett N, Warden MN, Odem-Davis K, VanDevanter DR, Ren CL, Young J, Konstan MW. Heterogeneity of CFTR modulator-induced sweat chloride concentrations in people with cystic fibrosis. J Cyst Fibros. 2024 Jul; 23(4):676-684.
-
Beswick DM, Khatiwada A, Miller JE, Humphries SM, Wilson A, Vladar EK, Lynch DA, Taylor-Cousar JL. Impact of highly effective modulator therapy on chronic rhinosinusitis and health status: 2-year follow-up. J Cyst Fibros. 2024 Mar; 23(2):214-218.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|